Open label study to confirm effectiveness, safety and pharmacokinetics of fentanyl transdermal matrix patch, in Japanese patients with cancer pain who have had a minimum amount of morphine therapy, such as equal to less than 45 mg/day of oral morphine or oxycodone equal to less than 30 mg/day

Trial Profile

Open label study to confirm effectiveness, safety and pharmacokinetics of fentanyl transdermal matrix patch, in Japanese patients with cancer pain who have had a minimum amount of morphine therapy, such as equal to less than 45 mg/day of oral morphine or oxycodone equal to less than 30 mg/day

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2011

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top